Selected Publications

Moon EK, Wang LC, Dolfi DV, Wilson CB, Ranganathan R, Sun J, Kapoor V, Scholler J, Puré E, Milone MC,  June CH, Riley JL, Wherry EJ, Albelda SM.  Multifactorial T cell Hypofunction that is Reversible Can Limit the Efficacy of Chimeric Antibody Receptor-transduced Human T cells in Solid Tumors. Clinical Cancer Res 20:4262-4273.2014. PMCID: PMC4134701

Eruslanov EB, Bhojnagarwala, P.S., Quatromoni, J.G., Stephen, T.L., Ranganathan, A, Deshpande, C., Akimova, T,  Vachani, A., Litzky, L., Hancock W., Conejo-Garcia, J.R., Feldman, M., Albelda, S.M., Singhal, S. Tumor-Associated Neutrophils Stimulate T Cell Responses in Early Stage Human Lung Cancer, J. Clinical Investigation, 124:5466-80. 2014. PMCID:  PMC4348966

Wang E, Wang LC, Tsai CY, Bhoj V, Gershenson Z, Moon E, Newick K, Sun J, Lo A, Baradet T, Feldman MD, Barrett D, Pure E, Albelda S, Milone MC.  Generation of potent T-cell immunotherapy for cancer using DAP12-based, multichain, chimeric immunoreceptors.  Cancer Immunol Res. 3:815-26. 2015. PMCID: 4490943.

Lo A, Wang LC, Scholler J, Monslow J, Avery D, Newick K, O'Brien S, Evans RA, Bajor DL, Clendenin C, Durham AC, Buza EL, Vonderheide RH, June CH, Albelda SM, Pure E.  Tumor-promoting desmoplasia is disrupted by depleting FAP-expressing stroma cells.  Cancer Res. 75:2800-10. 2015.  PMCID: PMC4506263.

Moon EK, Ranganathan R, Eruslanov E, Kim S, Newick K, O'Brien S, Lo A, Liu X, Zhao Y, Albelda SM.  Blockade of Programmed Death 1 Augments the Ability of Human T cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer. Clin Cancer Res. 22: 436-447, 2016  PMCID: PMC4715990.

Newick K, O’Brien S, Sun J, Kapoor V, Maceyko S, Lo A, Pure E, Moon E, Albelda SM.  Augmentation of CAR T cell trafficking and antitumor efficacy by blocking protein kinase A (PKA) localization. Cancer Immunol Res 4:541-51, 2016. PMCID: PMC4891259.

Newick K, Moon E, Albelda SM.  Chimeric antigen receptor T cell therapy for solid tumors. Mol Ther Oncolytics 3:16006, 2016. PMCID: PMC4849432.

Sterman DH, Alley E, Stevenson JP, Friedberg J, Metzger S, Recio A, Moon EK, Haas AR, Vachani A, Katz SI, Sun J, Heitjan D, Hwang, WT, Litzky L, Yearley JH, Tan KS, Papasavvas E, Kennedy P, Montaner LJ, Cengel KA, Simone CB 2nd, Culligan  M, Langer CJ, Albelda SM.  Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα  Combined with Chemotherapy.  Clin Cancer Res 22:3791-800, 2016. PMCID: PMC4970934.

Singhal S, Bhojnagarwala PS, O’Brien S, Moon EK, Garfall AL, Rao AS, Quatromoni JG,  Stephen TL, Litzky L, Deshpande C, Feldman MD, Hancock WW,  Conejo-Garcia JR, Albelda SM, Eruslanov EB.  Origin and Role of a Subset of Tumor-Associated Neutrophils with Antigen-Presenting Cell Features in Early-Stage Human Lung Cancer.  Cancer Cell 30:120-35, 2016. PMCID: PMC4945447.

Wang L, Kumar S, Dahiya S, Wang F, Wu J, Newick K, Han R, Samanta A, Beier UH, Akimova T, Bhatti TR, Nicholson B, Kodrasov MP, Agarwal S, Sterner DE, Gu W, Weinstock J, Butt TR, Albelda SM, Hancock WW. Ubiquitin-specific Protease-7 Inhibition Impairs Tip60-dependent Foxp3+ T-regulatory Cell Function and Promotes Antitumor Immunity. EBioMedicine. 2016 Oct 15. pii: S2352-3964(16)30480-7. doi: 10.1016/j.ebiom.2016.10.018. [Epub ahead of print] PMID: 27769803

Condamine T, Dominguez GA, Youn JI, Kossenkov AV, Mony S, Alicea-Torres K, Tcyganov E, Hashimoto A, Nefedova Y, Lin C, Partlova S, Garfall A, Vogl DT, Xu X, Knight SC, Malietzis G, Lee GH, Eruslanov E, Albelda SM, Wang X, Mehta JL, Bewtra M, Rustgi A, Hockstein N, Witt R, Masters G, Nam B, Smirnov D, Sepulveda MA, Gabrilovich DI.  Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients.    Sci Immunol. 2016 Aug;1(2). pii: aaf8943. doi: 10.1126/sciimmunol.aaf8943. Epub 2016 Aug 5.  PMID: 28417112

Eruslanov E, Singhal S, Albelda SM. Mouse versus human neutrophils in cancer-a major knowledge gap.  Trends in Cancer, 2017, in press